You are here: Industry Insights > NSCLC

News List

AZ grabs EU approval for Imfinzi in advanced lung cancer pharmaphorum
September 27, 2018
The European Commission has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) in a kind of lung cancer that was previously only treatable with chemotherapy.
Takeda's lung cancer treatment Alunbrig proves successful in Phase III trial pharmafile
September 27, 2018
Japanese pharma firm Takeda have announced that lung cancer treatment Alunbrig has proven successful in reducing the risk of disease progression or death by more than 50%...
Roche to file entrectinib for ROS-1 positive NSCLC pharmatimes
September 27, 2018
Roche is planning to file its investigational cancer drug entrectinib following positive results from early and mid-stage trials with patients...
Merck extends I/O lead as EU Oks Keytruda in first line lung cancer biopharmadive
September 17, 2018
Keytruda (pembrolizumab) continues to dominate in first-line NSCLC approvals, which have fueled its rapid sales growth and transformed Merck into an immunotherapy leader.
AstraZeneca's Tagrisso gains approval in Japan for the first-line treatment of patients with NSCLC firstwordpharma
August 22, 2018
AstraZeneca announced Tuesday that the Japanese Ministry of Health, Labour and Welfare approved Tagrisso (osimertinib) for the first-line treatment of patients with inoperable or recurrent EGFR mutation-positive non-small-cell lung cancer (NSCLC).
Roche's Alecensa receives 'priority review' designation from CNDA biospectrumasia
August 22, 2018
Alecensa is now approved in over 57 countries around the world as an initial (first-line) treatment for ALK-positive advanced NSCLC, including the US, Europe and Japan
FMI test helps predict response to Roche's drug biospectrumasia
August 08, 2018
The study, demonstrates the potential of bTMB to expand precision oncology approaches for patients with advanced cancers, including metastatic lung cancer.
Medpacto inks deal with AstraZeneca biospectrumasia
August 03, 2018
Under the terms of the agreement, MedPacto and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in NSCLC
Sanofi and REVOLUTION Medicines launch global partnership to develop potential first-in-class targeted treatments for multiple cancers worldpharmanews
July 19, 2018
Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with non-small lung cancer and other types of cancer c
Pfizer files lung cancer drug in the EU, US pharmatimes
July 18, 2018
Pfizer has filed its pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib on both sides of the Atlantic for a particular form of lung cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page